Puretech founded entity vedanta biosciences enrolls first patient in pivotal phase 3 restorative303 study of ve303 for the prevention of recurrent c. difficile infection

Boston--(business wire)--puretech founded entity vedanta biosciences enrolls first patient in pivotal phase 3 study of ve303.

PRTC Ratings Summary

PRTC Quant Ranking